Related Experiment Video
Updated: Apr 19, 2026
A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth
Published on: December 22, 2020
Secreted frizzled-related protein 4 and its implications in cancer and apoptosis
Sebastian Pohl1, Ross Scott, Frank Arfuso
1School of Biomedical Science, Faculty of Health Sciences, Curtin University, GPO Box U1987, Perth, Western Australia, 6845, Australia, sebastian.pohl@postgrad.curtin.edu.au.
Abstract:
Secreted frizzled-related protein 4 (SFRP4) is a glycoprotein that acts as an antagonist of Wnt ligands, causing inhibition of the canonical Wnt signalling pathway. First noticed due to high expression levels during times of increased apoptosis, SFRP4 has been implicated in cell proliferation and differentiation and plays an important role in carcinogenesis. Many tumours such as endometrial, cervical, ovarian, prostate, bladder, colorectal, mesothelioma, pancreatic, renal, and oesophageal tumours are characterised by aberrant promoter hypermethylation, which causes variations in the expression level of SFRP4 when compared to normal cells. Combined experimental data appear to confirm the suggested role of SFRP4 as a local initiator of apoptosis; however, increased SFRP4 expression may not always correlate with an increase in apoptosis, possibly due to the complex interactions between different signalling pathways. SFRP4 can be explored for its use in novel therapeutic modalities as well as being a potential diagnostic biomarker.
Insights
Secreted frizzled-related protein 4 (SFRP4) is a key player in cell signaling and cancer. Aberrant SFRP4 expression, often due to gene methylation, impacts apoptosis and tumor development, suggesting its potential as a diagnostic biomarker and therapeutic target.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Signaling
Background:
- Secreted frizzled-related protein 4 (SFRP4) is a glycoprotein antagonist of Wnt ligands.
- SFRP4 inhibits the canonical Wnt signaling pathway, influencing cell proliferation, differentiation, and carcinogenesis.
- Aberrant promoter hypermethylation of SFRP4 is observed in various cancers, altering its expression levels compared to normal tissues.
Purpose of the Study:
- To investigate the role of SFRP4 in carcinogenesis.
- To explore the relationship between SFRP4 expression, apoptosis, and Wnt signaling.
- To evaluate SFRP4 as a potential diagnostic biomarker and therapeutic target in cancer.
Main Methods:
- Analysis of SFRP4 expression levels in tumor tissues.
- Investigation of promoter hypermethylation patterns.
- Correlation studies between SFRP4 expression and apoptosis.
- Examination of SFRP4's interaction with Wnt signaling pathways.
Main Results:
- SFRP4 expression is frequently altered in numerous tumors (e.g., endometrial, colorectal, prostate) due to promoter hypermethylation.
- Experimental data suggest SFRP4 can initiate local apoptosis, though this correlation is not always direct.
- Complex signaling pathway interactions may modulate the direct link between SFRP4 levels and apoptosis.
Conclusions:
- SFRP4 plays a significant role in cancer development and progression.
- SFRP4's altered expression and its role in apoptosis highlight its potential as a cancer biomarker.
- SFRP4 represents a promising candidate for novel cancer therapeutic strategies.
Related Concept Videos
02:54Canonical Wnt Signaling Pathway
02:23Abnormal Proliferation
01:31The Intrinsic Apoptotic Pathway
01:17The Extrinsic Apoptotic Pathway
01:41Non-Canonical Wnt Signaling Pathways
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...